Here are the 8-K filings from iTeos Therapeutics, Inc. (ITOS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ITOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ITOS filings page.
iTeos Therapeutics, Inc. has been acquired by Concentra Biosciences through a tender offer and follow-on merger. Stockholders received $10.047 in cash per share plus one non-transferable contingent value right (CVR) per share, providing potential future payments under a CVR agreement.
The tender offer expired on August 28, 2025, with 32,226,407 shares validly tendered, representing about 72.17% of outstanding shares, satisfying the minimum tender condition. On August 29, 2025, a merger under Delaware law made iTeos a wholly owned subsidiary of Concentra, and remaining shares were converted into the same cash-and-CVR consideration.
Trading in iTeos common stock on Nasdaq was suspended, and delisting and deregistration procedures have been initiated. As part of the change in control, the prior board members resigned at the merger’s effective time, and the directors and officers of the acquirer’s merger subsidiary, led by Kevin Tang, became the leadership of the surviving corporation.